Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also offers VRDN-006 that is in Phase 1 clinical trial and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Viridian Therapeutics Inc.

Viridian Therapeutics, Inc. ( ($VRDN) ) has released its Q3 earnings. Here is a breakdown of the information Viridian Therapeutics, Inc. presented ...

Market Cap	$1.59B	P/E Ratio	N/A
52W High	$29.90	52W Low	$9.90
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	22.8%	52W Position	102.2%
Overall Score	80	Value Score	60
Quality Score	--	Technical Score	100

EPS Current Est	$-3.2	EPS Next Est	$-3.37
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VRDN	$30.34	+2.95%	2.11M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	VRDN	$30.34	+3.0%	2.11M
3
4
5
6

VRDN

VRDN

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Viridian Therapeutics Inc. Data in Excel

Get Viridian Therapeutics Inc. Data in Excel